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TO THE EDITOR
Cyclin-dependent kinase inhibitor 2A
(CDKN2A/p16) is a high-penetrance,
autosomal-dominant melanoma predis-
position gene (Cannon-Albright et al.,
1992; Kamb et al., 1994) and mutations
of this tumor suppressor are associated
with a markedly increased risk of
melanoma (Goldstein and Tucker,
1995; Kefford et al., 1999). CDKN2A/
p16 activity is required for melanocyte
senescence in vitro (Gray-Schopfer
et al., 2006). Pathogenic mutations
have been discovered in approximately
10% of Utah melanoma pedigrees
(Eliason et al., 2006). We recently
reported in the Journal the results of a
longitudinal follow-up study of mem-
bers of a Utah melanoma-prone kin-
dred with a temperature-sensitive
V126D CDKN2A/p16 mutation. Muta-
tion carriers accumulated significantly
more melanocytic nevi over a 15-year
interval than non-carrier family mem-
bers or spouse control subjects (Florell
et al., 2004). Moreover, carrier subjects
possessed more nevi on warm body
regions, such as the head, neck, and
trunk (Florell et al., 2005). These
findings suggest that in addition to
conferring melanoma susceptibility,
CDKN2A/p16 mutation contributes to
nevus development and distribution. To
this end, we hypothesized that (1)
pedigree members with a non-tempera-
ture-sensitive pathogenic CDKN2A/p16
mutation would possess more melano-
cytic nevi and have a larger nevus
density than non-carrier subjects; and
(2) a temperature-sensitive nevus dis-
tribution would not be identified. To
obtain additional evidence regarding
the effect of a different CDKN2A/p16
mutation on nevus formation, we stu-
died a second Utah melanoma pedigree
with a promoter-region (G-34T)
CDKN2A/p16 mutation in the 50 un-
translated region that results in a false
initiation site with reduced translation
of wild-type CDKN2A/p16 (Liu et al.,
1999) and segregates with melanoma
susceptibility in melanoma pedigrees
(Liu et al., 1999; Harland et al., 2000).
This study was approved by the
University of Utah Institutional Review
Board (Utah IRB no. 7916) and was
conducted according to the Declaration
of Helsinki principles utilizing informed
written consent. Thirty-one members
of the G-34T pedigree and 13 spouse
control subjects participated approxi-
mately 12 years earlier in this follow-
up examination. All subjects were
examined by the same dermatologist
(LJM) for the initial and follow-up
studies. Neither the participants nor
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Figure 1. Comparison of TNN and TND in V126D and G-34T CDKN2A/p16 kindreds.Mutation carriers
in both kindreds have larger TNN and TND than non-carrier and spouse control subjects. V126D
mutation carriers had larger TNN and TND than G-34T mutation carriers, but the differences were not
significant. Box-and-whiskers plot representing median (horizontal line within box), mean (diamond),
upper quartile, lower quartile, and range of values for TNN and TND by carrier group. I, initial
examination; F/U, follow-up examination (B12 years following initial examination).
Abbreviations: TND, total nevus density; TNN, total nevus number
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the examiner were aware of the
CDKN2A/p16 mutational status. The
initial and follow-up studies included
a total body skin examination in which
the location and size of all nevi that
were X2mm in diameter were re-
corded on a body map diagram. Warm
regions were defined as the head, neck,
and trunk and cold regions as the upper
and lower extremities. Total nevus
number (TNN) was defined as the
number of clinically detectable nevi
X2mm in diameter. Total nevus den-
sity (TND) was estimated by calculating
the area of all nevi divided by the
estimated body surface area of the
individual, as described previously
(Goldgar et al., 1991; Meyer et al.,
1992). Mutational status of the family
members was determined by sequen-
cing the promoter region and exons
1a–3 of CDKN2A/p16 and exon 1b (ARF)
or by site-specific screening for G-34T.
Genetic testing was performed at one of
three CLIA-certified laboratories, includ-
ing GeneDx Inc. (Gaithersburg, MD),
Myriad Genetic Laboratories (Salt Lake
City, UT), or Yale Diagnostic Laboratory
(New Haven, CT). TNN and TND data
were analyzed using multiple linear
regression with carrier status, age at first
visit, and gender as predictors (Florell
et al., 2004). Nevus distribution data
were analyzed by absolute number of
nevi and by the mean change of nevi in
warm and cold regions of the body over
time using two-sided Mann–Whitney
U-test (Florell et al., 2005).
Seven carrier subjects were male
and 5 were female with a mean age of
37 years at the initial and 49 years at
the follow-up examination; 10 non-
carrier subjects were male and 9 were
female with a mean age of 34 years at
the initial and 46 years at the follow-up
examination; 5 spouse control subjects
were male and 8 were female with a
mean age of 45 years at the initial and
59 years at the follow-up examination.
The mean follow-up period was 11.3,
12.6, and 14.0 years for the mutation
carrier, non-carrier, and spouse control
subjects, respectively.
Similar to the V126D CDKN2A/p16
pedigree, G-34T mutation carriers
(n¼12) had significantly larger TNN
and TND over the follow-up interval
Table 1. Nevus phenotype characteristics among mutation carriers, non-carriers, and spouse control subjects
Response Mean carrier Mean non-carrier Unadjusted difference Adjusted difference (95% CI) P-value
Carrier compared with non-carrier
Initial TNN 31.8 15.9 15.9 16.5 (3.3–30.0) 0.016
Final TNN 42.8 22.6 20.2 21.3 (1.5–41.1) 0.036
Change in TNN 11.0 6.7 4.3 4.8 (5.0–14.6) 0.32
Initial TND 134.5 61.5 73.0 76.3 (19.3–133.4) 0.011
Final TND 144.8 72.9 71.9 74.9 (9.1–140.8) 0.027
Change in TND 10.3 11.4 1.1 1.4 (58.5–55.7) 0.96
Carrier compared with spouse controls
Initial TNN 31.8 12.7 19.1 12.2 (2.0–26.4) 0.089
Final TNN 42.8 9.0 33.8 24.4 (4.2–44.4) 0.020
Change in TNN 11.0 3.7 14.7 12.2 (2.2–22.4) 0.020
Initial TND 134.5 39.8 94.7 73.2 (9.2–137.2) 0.027
Final TND 144.8 39.0 105.8 81.4 (9.4–153.2) 0.029
Change in TND 10.3 0.7 11.0 8.0 (51.4–67.4) 0.78
Non-carrier compared with spouse controls
Initial TNN 15.9 12.7 3.2 0.8 (8.4–10.0) 0.86
Final TNN 22.6 9.0 13.6 9.2 (4.0–22.4) 0.16
Change in TNN 6.7 3.7 10.4 8.4 (0.17–16.7) 0.046
Initial TND 61.5 39.8 21.7 12.8 (26.4–51.9) 0.51
Final TND 72.9 39.0 33.9 18.4 (26.6–63.4) 0.41
Change in TND 11.4 0.7 12.1 5.7 (34.4–45.7) 0.77
CI, confidence interval; TND, total nevus density; TNN, total nevus number.
The ‘‘unadjusted difference’’ is the difference between the means of the two groups. The ‘‘adjusted difference’’ accounts for differences in age and gender
among the genotypic groups. Note that the ‘‘change in TNN’’ and ‘‘change in TND’’ between carriers and non-carriers over the follow-up interval are not
significant, suggesting that the difference in TNN and TND is present by the time of the initial visit. The incremental change in TNN and TND between visits
appears to be approximately the same for carriers and non-carriers. These are F-tests for the ‘‘group’’ effect from multiple linear regression analyses, with age
as a continuous predictor and gender and group as factors. In each analysis, the group factor had two levels (carrier and non-carrier, or carrier and spouse, or
non-carrier and spouse).
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compared with non-carrier (n¼19;
P¼0.04 TNN; P¼ 0.03 TND; multiple
regression) and spouse control subjects
(n¼13; P¼0.02 TNN; P¼ 0.03 TND;
multiple regression) (Figure 1; Table 1).
The non-carrier subjects had an inter-
mediate TNN and TND between carrier
and spouse control subjects at the initial
and follow-up examinations, although
differences were not significant
(Figure 1; Table 1). Mutation carriers
developed a median of 0.76 nevi
(per year) (range 0.09–4.37, mean±SD
1.08±1.25) versus 0.30 nevi (range
0.01–2.39, mean 0.59±0.72) for
non-carriers and 0.14 nevi (range
0–0.58, mean 0.02þ0.21) for spouse
control subjects (carrier versus non-
carrier P¼0.33; carrier versus spouse
control P¼ 0.003; non-carrier versus
spouse control P¼0.014; two-sided
Mann–Whitney U-test). However,
unlike the V126D pedigree, a tempera-
ture-sensitive distribution was not ob-
served in the G-34T pedigree; similar
changes were seen in TNN and TND in
warm (P¼ 0.70 and P¼0.48, respec-
tively; two-sided Mann–Whitney U-test)
and cold (P¼ 0.13 and 0.73, respec-
tively; two-sided Mann–Whitney U-test)
regions among mutation carriers and
non-carriers. Carrier subjects had sig-
nificantly more clinically atypical nevi
than non-carrier subjects (carriers:
median 4, range 0–9, mean 4 atypical
nevi; non-carriers: median 0, range
0–11, mean 2 atypical nevi; P¼0.03;
two-sided Mann–Whitney U-test). Six
carriers (50%) and one non-carrier
(5.3%) had invasive malignant melano-
ma (P¼ 0.007; Fisher’s Exact Test).
Significant differences in Fitzpatrick
skin type and markers of chronic UV
irradiation (rhytides, poikiloderma,
solar lentigines, actinic keratoses, and
so on) were not identified among the
genotypic groups (data not shown).
Increased numbers of cutaneous
melanocytic nevi are a well-known
and major risk factor for cutaneous
melanoma (Swerdlow et al., 1986;
Bataille et al., 1996, 1998; Kefford
and Mann, 2003). Of all known risk
factors, inheritance of a pathogenic
CDKN2A/p16 mutation confers the
highest risk, although the nevus pheno-
type correlates poorly with genotype
(Bishop et al., 2000). Indeed, in our
previous study, we noticed that the
nevus phenotype was quite variable
within genotypic groups (Florell et al.,
2004) suggesting coexistence of addi-
tional nevogenic genes or modifying
loci. Nonetheless, CDKN2A/p16 muta-
tion carriers in this 34G4T pedigree
as well as the previously studied V126D
pedigree had significantly more nevi
and a larger nevus density than non-
carrier or spouse control subjects and
continued to develop additional nevi at
a faster rate than non-carrier subjects.
However, carrier subjects from the
34G4T pedigree have fewer nevi
than carrier subjects from the V126D
pedigree (Figure 1), although the differ-
ence is not significant. It is possible that
the number of subjects may not be
sufficient to detect a small difference
between the two pedigrees and among
the genotypic groups.
In summary, these longitudinal fol-
low-up data from a second CDKN2A/
p16 melanoma family (1) confirm our
previous observation that CDKN2A/p16
mutations are associated with a higher
nevus number and density, although
differences in the rate of nevus devel-
opment were not identified among
mutation carriers and non-carriers in
this pedigree; (2) fail to demonstrate a
temperature-sensitive distribution, add-
ing additional support to our observa-
tion that a temperature-sensitive
CDKN2A/p16 mutation may confer a
temperature-sensitive nevus distribu-
tion; and (3) demonstrate that the
absolute nevus count is not a useful
marker of CDKN2A/p16mutation status
in the clinical setting due to the
considerable variability between
genotypic groups and pedigrees.
These findings provide additional evi-
dence that the presence of a CDKN2A/
p16 mutation promotes nevus develop-
ment and the type of mutation can
influence nevus distribution, and
suggest a clinical correlation between
the nevus phenotype and melanocyte
senescence.
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TO THE EDITOR
Cancer is a disease largely dependent
on neoangiogenesis. Accumulating
evidence indicates that tumor angio-
genesis is supported by the mobiliza-
tion and incorporation of endothelial
progenitor cells (EPCs), highly prolif-
erative elements derived from the bone
marrow (Rafii et al., 2002). EPCs have
been detected at increased frequency in
the circulation of patients with different
types of cancer, in some cases even
correlated with tumor volume, so that
they have been proposed to possibly
represent a diagnostic and prognostic
tool to be used as a surrogate marker
in clinical studies (Bertolini et al., 2006).
To our knowledge, circulating EPCs
have never been quantified in patients
with Kaposi’s sarcoma (KS), an angio-
proliferative malignancy in which the
typical spindle-shaped tumor cells
share many markers with vascular endo-
thelial cells and are thought to be of
endothelial origin (Dupin and Grange,
2006).
Circulating EPCs can be defined by
the expression of cell-surface antigens.
Although a unique consensus on the
optimal markers to be used is still
lacking, current literature supports that
CD34þKDRþ is still the best antigenic
combination to define EPCs (Fadini
et al., 2007), as only the level of
CD34þKDRþ cells has been shown
repeatedly and convincingly to be an
independent predictor of cardiovascu-
lar events (Werner et al., 2005;
Schmidt-Lucke et al., 2005). In a pre-
vious study, we reported that CD34þ
cells, which contain EPCs, are
increased in patients with KS (Della
Bella et al., 2006). In this study, by
flow cytometry we analyzed the
frequency of EPCs, either identified
as CD34þKDRþ cells or as CD34þ
KDRþCD133þ cells, in the peripheral
blood of patients with classic KS (cKS)
compared with matched healthy con-
trols. The selection of patients affected
by the classic variant of the disease was
aimed to avoid the confounding effects
of HIV co-infection or immunosuppres-
sive therapy that are present in the other
clinical variants of KS. All patients
had histologically confirmed diagnosis
of KS, were positive for anti-human
herpesvirus-8 (HHV8) antibodies,
and negative for HIV. Staging was
performed in accordance with our
classification (Brambilla et al., 2003).
Circulating EPCs were measured at a
single time point on fresh peripheral
blood samples; staging at this time
is summarized in Table 1. Ethical
approval was obtained from the local
Institutional Review Committee, and
signed informed consent was obtained
from all participants. The study was
conduced according to the Declaration
of Helsinki Principles. Heparinized
whole-blood samples (100 ml) were
incubated with biotin-conjugated anti-
human kinase insert domain receptor
(KDR) (Sigma-Aldrich, St Louis, MO),
phycoerythrin-conjugated anti-human
CD133 (Miltenyi-Biotec, GmbH,
Bergisch Gladbach, Germany), and phy-
coerythrin-Cy5-conjugated anti-human
CD34 (Beckman-Coulter Immunotech,
Marseille, France) mAbs. KDR was
Abbreviations: cKS, classic Kaposi’s sarcoma; EPC, endothelial progenitor cell; HHV-8, human
herpesvirus-8; KDR, kinase insert domain receptor; KS, Kaposi’s sarcoma
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